Charged Alpha Stock Encyclopedia

Charged Alpha Stock Encyclopedia

By Colton ThomasBusinessInvesting
Download on the App Store

Charged Alpha Stock Encyclopedia episodes

  • Quantum Computing (QUBT) Q2 2026 Earnings: Revenue Up 91x, Like-For-Like It FELL 42%
    Quantum Computing, Inc. (QUBT) Q2 2026 — Revenue $5.551M vs $61K a year ago (about 91x) and $3.691M in March, beating a $5.1515M bar by 7.8%. GAAP EPS -$0.05 vs a -$0.0345 bar, a miss. The 8-K was accepted 4:23pm ET Mon Aug 10 (AMC), so Tuesday Aug 11 IS the reaction: $8.93 to $8.95, up 0.22%, after gapping up to $9.16 - which was also the high - and fading to close at $8.95 on 0.67x average volume.
    The headline is revenue up from $61 thousand to $5.551 million - about 91 times. But the company's own pro-forma table in Note 3 of the 10-Q restates both years as if the three businesses QCi bought in 2026 had always been owned, and like-for-like combined revenue FELL from $15.755M to $9.076M - down 42.4%. Every dollar was sold below cost, at a -21% gross margin, while interest income of $12.954M was 2.33x the revenue of the actual business.
    THE CALL: SELL (3/5, PRICE CALL, NOT A BUSINESS-QUALITY CALL) — base-case value ~$7.25 vs ~$8.95 today.
    KEY METRICS:
    - CALL: SELL 3/5, fair value $7.25 vs the $8.95 close - about 19% below, and 58% under the $17.33 Street consensus. H1 free cash flow -$27.785M, so we use a sum-of-the-parts, not a DCF. Bull $11.50 / base $6.75 / bear $5.00. Conviction 3 not 5 because $5.85 a share of Treasuries is a hard floor.
    - THE PRINT: revenue $5.551M vs $61K (about 91x), +50.4% on March's $3.691M, beating a $5.1515M bar by 7.8%. But cost of revenue was $6.717M - a GROSS LOSS of $1.166M, a -21.0% margin, against +43% a year ago. Opex $21.847M (+114%) including $7.3M of deal costs. Operating loss $23.013M.
    - EPS BASIS PROVEN: -$11,753k / 224,727k shares = -$0.0523 GAAP. There is NO non-GAAP EPS in the release, so the -$0.0345 bar is GAAP and the miss is real. Quarters tie: March -$0.02 + June -$0.05 = the filed H1 -$0.07. Revenue ties: $3.691M + $5.551M = $9.242M. All 6,308k dilutive shares are antidilutive.
    - THE ANGLE - THE PRO-FORMA: Note 3 of the 10-Q restates both years as if LSI, NuCrypt and NHanced had always been owned. June-quarter revenue went $15.755M to $9.076M - DOWN 42.4%. Six months: $30.504M to $18.879M, -38.1%. NHanced alone fell $10.399M to $3.525M (-66.1%) and went from +$2.398M to a -$3.229M loss.
    - WHAT $186.812M BOUGHT: LSI closed Feb 2 for $108.499M ($97.499M cash) on $32.638M of identifiable net assets - goodwill $75.861M, 70% of the price. NuCrypt Mar 4, $4.529M. NHanced Jun 22, $73.784M plus up to $72.0M earnout. Goodwill went $55.573M to $181.455M - $125.882M new, 67% of the spend.
    - BALANCE SHEET: cash $189.150M, short-term investments $765.020M, long-term $369.284M = $1.3235B, against $47.165M of total liabilities and NO debt. The book is $546.593M of Treasuries and $577.815M of corporate debt. Interest income $12.954M is 2.33x revenue and covers ~93% of the ~$55.6M burn.
    - VALUATION AND STREET: 226.346M shares at $8.95 = $2.026B; less $1.3235B cash, EV is about $702M - 19.3x pro-forma annualised sales at a -21% gross margin. RUN BACKWARDS: at 4x sales that EV needs ~$176M of revenue, 4.8x the $36.3M run rate, while the run rate SHRINKS 42%. Street: Buy, $17.33, every target predates this filing.
    What to watch: UP: $1.3235B of cash and securities ($5.85 a share, 65% of the price), NO debt, and total liabilities of just $47.165M; interest income covers ~93% of the cash burn, so there is no funding cliff; backlog $42.5M, 7.7x quarterly revenue; a real room-temperature photonic architecture and two fabs. DOWN: the company's own pro-forma says combined revenue fell 42.4%; gross margin is -21%, so growth destroys gross profit; NHanced fell 66.1% and flipped to a -$3.229M loss; $125.882M of new goodwill is 67% of the spend.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    13 min
  • Ambiq Micro (AMBQ) Q2 2026 Earnings: 90% Growth, And A Guide That Doubles The Loss
    Ambiq Micro, Inc. (AMBQ) Q2 2026 — Net sales $33.901M, up 89.7% y/y and 35.3% q/q, beating a $31.51M bar by 7.6%. Non-GAAP EPS -$0.07 vs -$0.257, a 19-cent beat. GAAP EPS -$0.32. The 8-K was accepted 7:31am ET Tue Aug 11 (BMO), so Tuesday IS the reaction: $63.92 to $65.29, up 2.14% - after an 8.7% intraday swing.
    Ambiq's June quarter was the best it has ever printed: net sales $33.901 million, up 89.7%, gross margin up 490 basis points, and the non-GAAP loss cut to seven cents against a 26-cent bar. Revenue rose 35.3% sequentially on operating expense up 6.8% - textbook operating leverage. Then the same press release guided September revenue up 7.7% at the midpoint and non-GAAP operating expense up 26.5%, which takes the non-GAAP operating loss from $3.385 million to about $7.35 million. The best quarter in company history came with a guide that un-prints it, and the stock closed up 2.1%.
    THE CALL: SELL (3/5, PRICE CALL, NOT A BUSINESS-QUALITY CALL) — base-case value ~$36.0 vs ~$65.29 today.
    KEY METRICS:
    - CALL: SELL 3/5, fair value $36 vs the $65.29 close - about 45% below, level with the Street's lowest published target. H1 free cash flow -$26.6M, so we use a path-to-profitability grid, not a DCF. Bull $58 / base $26 / bear $11, weighted = $30; a 4-6x peer sales check gives $33-$43. Blended $36.
    - THE PRINT: net sales $33.901M vs $17.873M (+89.7%), +35.3% on Q1's $25.060M, beating a $31.51M bar by 7.6%. GAAP gross margin 45.0% vs 40.1% (+490bp); non-GAAP 47.2% vs 42.7%. GAAP operating loss $8.727M vs $8.797M - FLAT on 90% more revenue.
    - EPS BASIS PROVEN: -$7,115k / 21,742,929 shares = -$0.32 GAAP; non-GAAP -$1,772k = -$0.07. The -$0.257 bar is non-GAAP, so the beat is 19 cents like-for-like. GAAP Q1 -$0.50 + Q2 -$0.32 = filed H1 -$0.82. No basis switch. The -$18.96 some screens show is a PRE-LISTING figure on 449,785 weighted shares - a denominator, not a charge.
    - THE GUIDE - THE STORY: Q3 net sales $36.0-37.0M is +7.7% q/q at the midpoint, but non-GAAP opex goes $19.374M to $24.0-25.0M (+26.5%) for 'planned intellectual property investments', and gross margin is guided to a 47.0% midpoint, 20bp BELOW the 47.2% delivered. $36.5M at 47.0% less $24.5M opex = a -$7.35M operating loss vs -$3.385M. Margin -10.0% to -20.1%.
    - CONCENTRATION AND THE RECORD: three end customers were 28.9%, 24.4% and 24.2% of Q2 net sales - 78% of the quarter. The same three a year ago were 32.7%, 11.5% and 38.1%, so one account roughly quadrupled while the old largest grew ~20%. And FY2024 net sales were $76.067M against FY2025's $72.514M - a 4.7% DECLINE in the year Ambiq listed.
    - BALANCE SHEET AND DILUTION: cash $366.774M vs $140.275M, and NO debt. H1 operating outflow $20.678M includes $22.670M of receivable and inventory build - strip working capital and the burn is nearer $6M. Shares 18,316,928 to 24,184,536, +32.0% in seven months, via follow-ons on 26 Jan at $31.00 and 25 June at $78.00.
    - VALUATION AND STREET: 24,184,536 shares = $1.579B; less $366.8M cash, EV is $1.212B - 8.75x our ~$138.5M 2026 estimate. RUN BACKWARDS: at a 15% terminal FCF margin and 20x exit that EV needs $830M of 2031 revenue, a 43% CAGR for five years. Street: consensus $79, median $78, high $125 (Roth, 13 Jul), low $35 (Needham, 5 Mar).
    What to watch: UP: a patented subthreshold platform 15 years in the making, 300M+ devices shipped, net sales +89.7% with gross margin +490bp, a guide limited by SUPPLY not demand, and $366.8M of cash with no debt. DOWN: net sales FELL 4.7% in 2025, three end customers are 78% of the quarter, the guide more than doubles the operating loss, the share count is +32% in seven months, and the EV is 8.75x our 2026 sales.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    15 min
  • Aeva Technologies (AEVA) Q2 2026 Earnings: The Product Line Fell 39%
    Aeva Technologies, Inc. (AEVA) Q2 2026 — Total revenue $6.136M, up 11.3% y/y - but PRODUCT revenue FELL 39.4% to $2.546M while professional service fees rose 174.5% to $3.590M. Non-GAAP EPS -$0.41 vs a -$0.43 bar, a 2-cent beat. The 8-K was accepted 4:10pm ET Wed Aug 5 (AMC), so Thu Aug 6 is the reaction: $19.61 to $25.26, UP 28.81% on 8.43M shares; $26.62 by Fri Aug 7.
    Aeva's headline read revenue up 11.3% and a two-cent beat, and the stock rose 28.81% the next day. Underneath it, product revenue - the part that actually ships - fell 39.4%, from $4.203 million to $2.546 million. All of the growth came from professional service fees, up 174.5%. A $1.856 billion company sold $2.5 million of product.
    THE CALL: SELL (4/5, PRICE CALL, NOT A BUSINESS-QUALITY CALL) — base-case value ~$12.50 vs ~$26.62 today.
    KEY METRICS:
    - CALL: SELL 4/5, fair value $12.50 vs the $26.62 close - about 53% below, and below the Street's lowest target. Free cash flow was -$59.4M in six months, so we use a path-to-profitability grid, not an owner-earnings DCF. Bull $36 / base $9 / bear $3.50, weighted 35/45/20 = $12.48.
    - THE PRINT: total revenue $6.136M vs $5.511M (+11.3%), and DOWN 2.0% against Q1's $6.262M. Gross profit $2.189M, a 35.7% margin, vs -$2.720M. GAAP operating loss $34.560M vs $34.923M - flat. Non-GAAP operating loss $26.047M vs $25.114M - WORSE year on year. R&D +9.0%, G&A +28.2%.
    - EPS BASIS PROVEN: -$79.624M over 64,672,666 weighted shares is -$1.2312, the filing's -$1.23 GAAP. Add back SBC $8.513M and the $44.700M warrant fair-value change for -$26.411M, or -$0.41 non-GAAP. The -$0.43 bar is non-GAAP too, so the beat is like-for-like and it is 2 cents. Q1 -$0.41 plus Q2 -$0.41 = the reported H1 -$0.82. No basis switch.
    - THE MIX FLIP - THE STORY: product revenue FELL 39.4%, from $4.203M to $2.546M. Professional service revenue - engineering fees recognised over time - ROSE 174.5%, from $1.308M to $3.590M. The mix went from 76% product / 24% service to 41% / 59%. North America fell 27.4%; EMEA went $0.489M to $2.574M.
    - THE LOSS THAT DOUBLED IS THE RALLY: of the $79.624M GAAP net loss, $44.700M is a NON-CASH mark on 3,000,000 Sylebra Series A warrants struck at $5.00. The liability went from $29.711M to $73.961M because the STOCK ROSE. Strip it out and the loss barely moved from Q1.
    - THE LIQUIDITY HEADLINE: $302.9M of 'total available liquidity' is $177.9M of cash and securities plus a $125M Sylebra standby line - 7% preferred, a $12,000 liquidation preference per $10,000 share, senior to common - that EXPIRES 8 Nov 2026 and needs a new 50,000-unit OEM award to draw. Burn was $57.015M operating plus $2.410M capex in H1, about $29.7M a quarter, roughly six quarters of runway.
    - WHAT $26.62 BUYS: 69,705,758 shares on the 10-Q cover dated 30 July = $1.856B. Add 11.29M options/RSUs/PSUs, 6.30M convertible-note shares at $15.86 and 3.00M warrants at $5.00 for 90.29M fully diluted. EV = $1.856B less $177.9M cash plus $96.9M of converts = $1.775B, or 82.2x TTM revenue of $21.598M.
    - STREET: 6 Buy, 2 Hold, 0 Sell. Consensus target $31.67 - but the MEDIAN is $27 and the stock is $26.62. Oppenheimer $42 (Aug 6, 2026), Morgan Stanley $27 (Aug 7, 2026), Canaccord Genuity $26 (Aug 6, 2026). The Street models 2027 revenue $70.9M and 2028 $208.2M, with first profitability in 2029.
    What to watch: UP: a differentiated FMCW lidar-on-chip platform, Daimler Truck, NVIDIA DRIVE Hyperion, SICK and Bendix, gross margin positive at 35.7%, and a credible route into AI data-centre optics. DOWN: product revenue -39.4%, non-GAAP operating loss worse y/y, $125M of liquidity expires 8 Nov 2026, and the EV is 82x sales.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    15 min
  • Arteris (AIP) Q2 2026 Earnings: The Real Forecast Was In The CFO’s Contract
    Arteris, Inc. (AIP) Q2 2026 — Record revenue $24.134M, up 46% and above consensus - but non-GAAP EPS -$0.10 against a -$0.04157 bar, a six-cent MISS on cost. ACV plus royalties $99.5M, up 44%. The 8-K was accepted 4:13pm ET Thu Aug 6 (AMC), so Fri Aug 7 is the reaction: $31.62 to $29.78, DOWN 5.82%.
    Arteris printed four company records and the stock fell 5.82%. The document nobody read was filed at 8:30 the same morning: an 8-K appointing a new CFO whose performance award vests on $200,000,000 of trailing revenue by end-2030. From the company's own $95-98M guide that is a 20.0% compound rate. Arteris just reported 46%.
    THE CALL: HOLD (3/5, PRICE CALL, NOT A BUSINESS-QUALITY CALL) — base-case value ~$28.35 vs ~$29.78 today.
    KEY METRICS:
    - CALL: HOLD 3/5, fair value $28.35 vs the $29.78 close - about 5% below, and 32% below the Street's $42. Path-to-profitability grid to 2030 at an 11% discount: bull $47 / base $27 / bear $14, weighted 30/45/25.
    - THE PRINT: revenue $24.134M vs $16.502M (+46.2%), above the $23.482M consensus and the $23-24M guide. Licensing $20.824M, royalties $2.103M, services $1.207M vs $0.012M. GAAP operating loss $13.908M; non-GAAP $4.569M. Gross margin 85% vs 89%.
    - EPS BASIS PROVEN: -$14.065M over 47,276,533 shares is -$0.29751 = the filed -$0.30 GAAP. Add back SBC $6.347M, intangible amortisation $0.777M and acquisition costs $2.215M: -$4.726M, or -$0.09996 = the filed -$0.10 non-GAAP. The -$0.04157 bar is that same basis, so the six-cent miss is real. Q1 -$0.03 + Q2 -$0.10 = the filed H1 -$0.13.
    - THE MISS IS COST, NOT REVENUE: non-GAAP operating expense went $22.576M (Mar) to $25.530M (Jun), up 13.1% in one quarter, on revenue up 5.2%. The non-GAAP operating loss nearly doubled, $2.519M to $4.569M.
    - THE LEADING METRIC WENT FLAT: ACV plus royalties exited Q2 at $99.5M (+44%), after $69.1M, $74.9M, $83.6M, $92.8M - five straight quarters of acceleration. Guidance: $99.0-103.0M for Q3 (low end BELOW $99.5M) and $102.0-106.0M exiting the year. The last three quarters added $8.7M, $9.2M, $6.7M; the next two add $4.5M. At 44%, December exits at $120.4M.
    - THE GUIDANCE LADDER: FY26 revenue $89-93M (Feb) to $91-95M (May) to $95-98M (Aug). ACV $100-104M to $102-106M to $102-106M, unchanged even though Q2 beat its own $95-99M range. Non-GAAP operating loss $5.0-9.0M to $4.5-8.5M to $7.0-10.0M: $3.5M more revenue with $5.5M more cost.
    - THE BOARD'S OWN FORECAST: an 8-K accepted 8:30am ET Aug 6 appoints Saurabh Sinha CFO from Sept 8, replacing Nick Hawkins. His inducement PSU vests on trailing-four-quarter revenue of $200,000,000 by Dec 31 2030, then a $65 close by Dec 31 2031. From the $96.5M guide midpoint that is a 20.0% CAGR; $65 is 15.4% a year.
    - VALUATION AND STREET: 49,051,892 shares at $29.78 is $1.461B, not the $1.375B float number on screens. Less $119.8M net cash, EV is $1.341B: 13.9x guided sales, 15.9x trailing, 13.5x ACV. Street 5 Buy / 2 Hold, average $42.00. Jefferies (Garrigan) upgraded to Buy, $50, Aug 7 2026; Roth $40 Aug 4; Oppenheimer $40 Jul 16; Northland $38 May 13.
    What to watch: UP: revenue +46%, trailing royalties +65%, design starts +21%, RPO $135M, 87% non-GAAP gross margin, $119.8M net cash, positive free cash flow, and a first non-GAAP operating profit implied in December. DOWN: ACV plus royalties guided from $99.5M to $102-106M exiting the year, the Q3 low end below what was just reported, and 4.78M new shares in six months.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    14 min
  • Voyager Technologies (VOYG) Q2 2026 Earnings: A Record Quarter, And A Third Of The Guide
    Voyager Technologies, Inc. (VOYG) Q2 2026 — Record net sales $52.746M, up 15.5% y/y - but gross profit FELL 45.7% to $4.457M, an 8.4% margin vs 18.0%. Adjusted EPS -$0.70 vs a -$0.87806 bar. Guidance raised to $275-305M. The 8-K was accepted 4:17pm ET Mon Aug 3 (AMC), so Tue Aug 4 is the reaction: $28.01 to $33.49, UP 19.56%; $41.85 by Fri Aug 7.
    Voyager raised full-year guidance to $275-305 million and the stock rose 70% in seven sessions. The arithmetic nobody ran: first-half net sales were $87.992 million - about a third of the low end. The second half has to carry $187-217 million against an H2 2025 of $86.238 million: 117% to 152% growth, at a company whose first half grew 9.7%.
    THE CALL: SELL (3/5, PRICE CALL, NOT A BUSINESS-QUALITY CALL) — base-case value ~$29.00 vs ~$41.85 today.
    KEY METRICS:
    - CALL: SELL 3/5, fair value $29 vs the $41.85 close - about 30% below, and below even the Street's lowest target. Free cash flow is negative, so we use a path-to-profitability scenario grid on exit multiples, not an owner-earnings DCF. Bull $60 / base $26 / bear $9, weighted 30/45/25 = $29.18.
    - THE PRINT: net sales $52.746M vs $45.674M (+15.5%). SG&A $43.672M vs $30.241M. R&D $7.336M vs $0.502M. Operating loss $51.408M vs $24.137M. Adjusted EBITDA -$37.500M vs -$9.066M. Free cash flow -$72.829M in Q2, -$139.623M in H1.
    - EPS BASIS PROVEN: -$46.490M over 58,521,968 weighted shares is -$0.7944, the filing's -$0.79 GAAP. Adding back SBC $3.762M, acquisition $2.008M, restructuring $0.966M, deferred tax -$2.179M and other $0.909M gives -$41.024M, or -$0.7010: the -$0.70 adjusted. The -$0.87806 bar is the same basis, so the 18-cent beat is real. Cross-check: Q1 -$0.61 plus Q2 -$0.70 equals the reported H1 -$1.31.
    - THE LINE NOBODY QUOTED: gross profit was $4.457M against $8.210M a year earlier. Revenue rose 15.5% and gross profit fell 45.7%. Gross margin went from 18.0% to 8.4%. Across the six months: $2.911M of gross profit on $87.992M of sales, a 3.3% margin against 17.2%.
    - THE GUIDANCE ARITHMETIC: the guide went $225-255M (Mar 9), $230-255M (May 4), $275-305M (Aug 3). H1 net sales were $87.992M, so H2 must deliver $187.0-217.0M against an H2 2025 of $86.238M - 117% to 152% growth, after an H1 that grew 9.7%. The next two quarters must average $93.5-108.5M against a record of $52.7M.
    - AND THE 10-Q, FILED THE NEXT MORNING: total backlog is $335.512M but only $189.008M is FUNDED; the other $146.504M is customer options not yet exercised. The filing expects 62.1% of funded backlog to convert in the rest of 2026 - $117.4M against a $187M requirement. A $70-100M gap must come from outside funded backlog. 87.7% of funded backlog is the U.S. government.
    - THE CAP TABLE SCREENS MISS: $460.0M of 0.75% converts due 2030 convert at $30.98 into 14,848,754 shares - deep in the money at $41.85, and excluded from diluted EPS as anti-dilutive in a loss year. Fully converted: 75.98M shares, $3.180B of equity, not the $2.535B on screens. Less $277M cash after Astrobotic, enterprise value is $2.903B: 10.0x guidance, 16.7x trailing sales.
    - STREET: 6 Buy, 0 Hold, 1 Sell. Consensus $54.40. Jefferies (Sheila Kahyaoglu) raised to $65 on Aug 9, 2026. Morgan Stanley (Kristine Liwag) cut to $37 on Aug 5, two days after the record print, keeping Underweight - the stock closed above it two days later.
    What to watch: UP: record bookings $113.0M at a 2.1x book-to-bill, backlog up 26.3% to $335.5M, $84.3M of Golden Dome awards, $585.5M of liquidity, three guidance raises with no miss. DOWN: the 10-Q funds only $117.4M of a $187M second half, gross margin is 8.4%, free cash flow was -$139.6M in six months.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    15 min
  • Spyre Therapeutics (SYRE) Q2 2026 Earnings: The 40-Cent Beat That Belongs To Somebody Else
    Spyre Therapeutics, Inc. (SYRE) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): no product revenue, ever. Net loss $36.200M vs $36.717M. EPS -$0.36 vs a -$0.759 bar - but the entire beat was a $40.0M pegzilarginase milestone on a drug sold in 2023, which the 10-Q says is owed to CVR holders. Ex-milestone EPS -$0.768: no beat. Cash $1,145.3M, no debt. Released 4:02pm ET Aug 4 (AMC), so Aug 5 is the reaction: $104.94 to $104.35, DOWN 0.56%.
    Spyre lost 36 cents against a 76-cent bar - a forty-cent beat at a company with no product and no revenue. The beat was a $40.0M milestone on pegzilarginase, a drug Spyre SOLD in 2023, triggered when the buyer sold a priority review voucher. That is 40.3 cents a share: the entire beat, to the cent.
    THE CALL: AVOID (3/5, GREAT SCIENCE, AND THE TAKEOUT PRICE IS ALREADY PAID) — base-case value ~$62.00 vs ~$104.91 today.
    KEY METRICS:
    - CALL: AVOID 3/5, fair value $62 vs the $104.91 close - about 41% below. No cash flows exist, so we use cash plus a probability-weighted sum of the parts, not a DCF. Bull $150 (takeout) / base $48 / bear $25, weighted 30/50/20 = $61.50.
    - THE PRINT, EPS BASIS PROVEN: R&D $65.503M (+63.2%), G&A $16.136M, net loss $36.200M vs $36.717M - flat on ~50% higher spend. Two-class method: common EPS -$0.36 and preferred -$14.60 recover the 40:1 conversion; 84,729,435 + 361,430x40 = 99,186,635 equivalents gives -$0.3650 exactly.
    - THE BEAT WAS THE MILESTONE, TO THE CENT: a $40.000M gain on sale of in-process R&D - a pegzilarginase milestone from the 2023 Immedica sale, triggered by the buyer selling a priority review voucher. $40.0M / 99,186,635 = $0.4033; the beat was $0.3939. Ex-milestone EPS -$0.768 vs -$0.759.
    - NOT SHAREHOLDERS' MONEY. 10-Q Note 10: milestone payments received by July 3, 2026 'will be distributed to CVR holders'. The CVR liability rose $34.873M in H1, $22.933M was paid out, $38.620M is still owed.
    - VALUATION: 88,064,133 common + 346,045 Series A preferred at 40:1 (13.84M) = 101.91M shares. At $104.91 that is a $10.69B market cap, not the $9.11B on screens. Less $1,145.3M cash, no debt: EV $9.55B. Cash $11.24/sh, the other $93.67 is pipeline.
    - THE REVERSE TEST: $9.55B of EV at a 2.75x peak-sales multiple and a 10% discount needs ~$22B of unrisked peak sales at 25% probability of success, or $9.3B even at a heroic 60%. Entyvio, the drug SPY001 targets, does ~$6.5B a year.
    - THE DATA IS OPEN-LABEL: SPY001 (n=43) cut Robart's Histopathology Index 9.2 points, 40% remission; SPY002 (n=48) cut it 10.7 points, 33%. Both p<0.0001, both SKYLINE Part A, which Spyre calls 'an open-label assessment'. Placebo-controlled Part B: 2027.
    - A FALSIFICATION WE PUBLISHED: we assumed anti-TL1A was broken. On June 22, 2026 Merck's tulisokibart met its primary endpoint in Phase 3 ATLAS-UC - the first anti-TL1A to win a Phase 3 in UC. It de-risks SPY002/SPY072, but Merck arrives first.
    - WHO SOLD: on June 23, a day after Merck's Phase 3 win, founding investor Fairmount sold 4,684,781 shares at $85.31 in one block - $399.7M (13D/A Amd 7). The CMO sold 20,000 at $100 on June 22; the CEO sold in June, July and Aug 3. ~$411M in ten weeks.
    - STREET: 12 Buy, 1 Hold, 0 Sell. Three raises the morning after - Wedbush $130, Baird $120, Wells Fargo $115, all Aug 5, 2026. High $135, low $49. Consensus $105.36 vs a $104.91 close: even the bulls see 0.4% upside.
    What to watch: UP: $1,145.3M cash, no debt, runway into 2H 2029; SPY001 and SPY002 both hit primary endpoints; Merck validated anti-TL1A in Phase 3 on June 22; six readouts in 2026. DOWN: the EPS beat is a milestone owed to CVR holders; every efficacy figure is open-label with no control until 2027; EV is $9.55B on $0 of revenue.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    15 min
  • Kulicke & Soffa (KLIC) Q3 FY2026 Earnings: The AI Multiple On A Ball-Bonder Boom
    Kulicke and Soffa Industries, Inc. (KLIC) Q3 FY2026 — Q3 FY2026 (quarter ended July 4, 2026): net revenue $330.409M, +122.6% y/y and +36.2% q/q. Non-GAAP EPS $1.20 vs a ~$1.06 bar and the company's own $1.00 May guide; GAAP EPS $1.07. Gross margin 47.8%. Q4 guided to $375M and $1.42. The 8-K landed 4:07pm ET Aug 5 (AMC), so Aug 6 is the reaction: $93.84 to $90.66, DOWN 3.39%.
    Revenue more than doubled to $330.4M and K&S beat its own guidance by twenty cents. But 68.4% of that was the legacy Ball Bonding line. Advanced Solutions - the thermocompression segment carrying the AI advanced-packaging story and most of the multiple - was 8.9% of revenue, LOST $12.6M, and gave back 1,210bps of gross margin.
    THE CALL: AVOID (2/5, A GENUINELY CLEAN QUARTER, AT 40x MID-CYCLE EARNINGS) — base-case value ~$59.00 vs ~$91.31 today.
    KEY METRICS:
    - CALL: AVOID 2/5, fair value $59 vs the $91.31 close - about 35% below, and below even our own $83 bull case. K&S is FCF-positive, so we use an owner-earnings DCF (10.5% discount) cross-checked against mid-cycle normalised earnings. Bull $83 / base $56 / bear $41, weighted 25/50/25 = $59.09. A price call, not a business-quality call.
    - THE PRINT, EPS BASIS PROVEN: revenue $330.409M (+122.6% y/y) vs $148.413M; GAAP EPS $1.07, non-GAAP $1.20. The $1.20 actual is the NON-GAAP line - proven, not assumed: the four FY2025 quarters (1.51, -1.59, -0.06, 0.12) sum to net income of $213K, the reported annual figure. Cleanest ruler: K&S guided this quarter to $310M and $1.00 on May 6.
    - TWO TESTS RUN, BOTH CLEARED - THE BEAT IS 100% OPERATIONAL. Tax: a $15.345M provision on $72.761M pre-tax, a 21.1% rate, and interest income FELL. Buyback decomposition: $64.228M non-GAAP net income over LAST year's 52.866M diluted shares = $1.21 vs the $1.20 reported, so repurchases cost a cent rather than adding one.
    - THE MIX IS THE STORY: Ball Bonding $226.068M (68.4% of revenue, +197.5%, $93.207M segment operating income). Advanced Solutions - die-attach and thermocompression - $29.415M (8.9%), an operating LOSS of $12.553M, gross margin 34.7% vs 46.8%, down 1,210bps on mix. APS $35.772M; Wedge $25.777M.
    - CONCENTRATION AND CAPITAL ALLOCATION: General Semiconductor drove $147.9M of the $182.0M increase. Three Chinese customers are 39.0% of nine-month revenue (Haoseng 14.8%, Tianshui Huatian 13.8%, Changjin 10.4%) and two are 49.8% of receivables. Net cash fell five straight quarters, $368.0M to $195.8M; repurchases were $7.3M vs $80.1M, with $226.4M still authorised.
    - THE FALSIFICATION WE PUBLISHED AGAINST OURSELVES: nine-month operating cash flow fell 55.7% to $46.554M while net income swung from -$6.166M to +$109.360M. But management's own working capital days went 450, 362, 323, 278, 214 - dramatically MORE efficient - and quarterly cash flow ran -$8.9M, $10.3M, $45.2M. The arithmetic of a ramp, not distress.
    - THE REVERSE TEST: at $91.31, 53.429M diluted shares = $4.88B market cap; less $516.573M cash and no borrowings = a $4.36B enterprise value. Run the model backwards and that needs roughly $1.83B of revenue in perpetuity at a 30% operating margin. K&S has touched $1.5B exactly twice and NEVER $1.8B; the ten-year average is $913M at a 15.3% through-cycle margin.
    What to watch: UP: revenue +122.6%, gross margin 47.8%, a beat that is 100% operational, $516.6M cash and ZERO borrowings, working capital days 450 to 214, Q4 guided to $375M. DOWN: the advanced-packaging segment is 8.9% of revenue and lost $12.6M; three Chinese customers are 39.0% of revenue; net cash has fallen five straight quarters; the price is 40x mid-cycle earnings.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    13 min
  • GRAIL (GRAL) Q2 2026 Earnings: The Beat The Tax Line Paid For
    GRAIL, Inc. (GRAL) Q2 2026 — Q2 2026: revenue $44.687M, +25.7% y/y, beating a ~$42.4M bar. Galleri volume +35% to more than 61,000 tests. Loss per share $2.56 vs a $2.66 estimate - a beat. But the operating loss WIDENED to $173.783M from $158.854M. The stock closed -14.53% on Aug 6, then rebounded 9.59% on Aug 7.
    GRAIL lost $2.56 a share against a $2.66 estimate and beat. Take out the $56.5M benefit from income taxes and the same quarter, on the same share count, is a loss of $3.87. That benefit is the unwind of a balance-sheet liability with only $133.7M left on it.
    THE CALL: AVOID (2/5, THE TEST IS IMPROVING; THE PRICE ALREADY PAYS FOR APPROVAL) — base-case value ~$52.00 vs ~$69.48 today.
    KEY METRICS:
    - CALL: AVOID 2/5, fair value $52 vs the $69.48 close (-25%), below a $65.17 Street target that is ITSELF below the price. GRAIL is deeply cash-flow negative, so we use path-to-profitability plus a reverse test, not an owner-earnings DCF: adjusted operating cost $447M/yr at a 48.2% adjusted gross margin needs ~$928M of revenue to break even, ~1.33M tests a year vs ~244K today. Bull $105, base $48, bear $15.
    - THE PRINT: revenue $44.687M, +25.7% y/y vs a ~$42.4M bar. Screening (Galleri) revenue $42.642M, +24%; volume 61,000+ tests, +35%. Adjusted gross profit $21.555M, +33.8%, a 48.2% adjusted gross margin vs 45.3%. Adjusted EBITDA loss $90.270M. Net loss $110.247M, $2.56/sh vs a $2.66 estimate.
    - THE BEAT IS A TAX LINE, PROVEN NOT ASSUMED: GRAIL publishes NO non-GAAP EPS, so the -$2.56 actual IS the GAAP line - the 2025 quarters -3.10 and -3.18 sum to the reported H1 -$6.28 exactly. Same ruler. But loss from operations WIDENED to $173.783M from $158.854M (-$14.9M) while the tax benefit rose $17.6M to $56.461M. Net loss improved only $3.7M.
    - THE FUSE: the tax benefit is the unwind of the deferred tax liability from the Illumina spin-off intangibles. FY2025 benefit $126.153M vs a DTL decline of $127.277M - one-to-one. The DTL was $218.583M in Dec and is $133.706M now. Roughly a year left. Ex-benefit this quarter is a $3.87 loss per share, not $2.56 - 51% worse from accounting alone.
    - UNIT ECONOMICS: Galleri revenue +24% against volume +35% means realised price per test fell ~8%, ~$761 to ~$699; the 10-Q says discounts and rebates keep reducing ASP. But cost of screening revenue rose only 20.7%, so cost per test fell ~10.6%, ~$428 to ~$383. Contribution margin 43.7% to 45.3%; gross profit per test still fell ~$333 to ~$316.
    - TWO CLOCKS AND THE PRICE: cash and securities $861.6M against H1 operating cash use of $167.719M (~$335M/yr) is ~10 quarters, to roughly Q1 2029 - the same year the Nancy Gardner Sewell Medicare MCED Act first opens a coverage pathway. Bridging means equity: $110M from Samsung in June, shares 40,331,360 to 44,666,234. At $69.48, EV is ~$2.24B = 13.6x trailing revenue of $165.3M; the reverse test needs ~2.1M tests a year by 2033, ~8.8x.
    What to watch: UP: Galleri volume +35% to 61,000+ tests, revenue +26% and a beat, cost per test down ~11%, adjusted gross margin 48.2%, $861.6M of cash with ZERO borrowings, an FDA panel on Sept 23 and a Medicare MCED pathway already in law. DOWN: the operating loss widened $14.9M; the improvement is a deferred-tax unwind with $133.7M left; break-even needs ~5.4x today's volume; cash runs to about early 2029.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    15 min
  • Ouster (OUST) Q2 2026 Earnings: 56% Growth Is 39% Like-For-Like
    Ouster, Inc. (OUST) Q2 2026 — Q2 2026: revenue $54.626M, +55.9% y/y, beating a ~$51.5M bar by ~6%. GAAP gross margin 48.85%, the best ever. Net loss $18.114M ($0.27/sh). Adjusted EBITDA loss $4.453M. Reported AMC Aug 6; the stock closed -4.78% on Aug 7 after trading up 8.6% intraday.
    Ouster grew revenue 55.9% to $54.6M. Put the Stereolabs acquisition into both years, as its own 10-Q does, and it is 44.1%. Take out $1.9M of patent royalties that were $34,000 a year ago and it is 39.3%. Still excellent - and 17 points below the headline.
    THE CALL: AVOID (2/5, THE BUSINESS IS IMPROVING; THE PRICE IS THE BULL CASE) — base-case value ~$24.00 vs ~$43.40 today.
    KEY METRICS:
    - CALL: AVOID 2/5, fair value $24 vs the $43.40 close (-45%), ~61% BELOW the $61.25 Street target. Ouster is FCF-negative, so we use a path-to-profitability model, not an owner-earnings DCF: 2026 revenue $219M compounding 20% for 9 years to $1.15B, FCF margin -6% next year to 18% terminal, discounted 11.5%. EV $1.32B (78% terminal) plus net cash over 72.11M shares = $21.90. Bull $43.67, bear $7.35, weighted $23.70.
    - THE PRINT: revenue $54.626M, +55.9% y/y and +12.5% q/q vs a ~$51.5M consensus. Product revenue $52.763M (+50.7%); royalties $1.863M vs $34,000 a year ago. GAAP gross profit $26.685M = 48.85% (42.90% in Q1, 45.20% a year ago); non-GAAP 53.5%. Operating loss $20.045M; net loss $18.114M, $0.27/sh. Adjusted EBITDA loss $4.453M. Q3 guide $54.5M-$57.5M.
    - THE EPS 'MISS' IS A BASIS MISMATCH, PROVEN NOT ASSUMED: screens showed -$0.26 vs a -$0.125 estimate. FY2025 GAAP quarters -0.42, -0.38, -0.37, +0.07 sum to -$1.10 vs a reported -$1.07, so the vendor ACTUAL is GAAP. But -$0.125 on 66.0M shares implies an $8.25M loss when stock comp ALONE was $11.385M. Actual GAAP, estimate not. We do not call it a miss.
    - THE GROWTH DECOMPOSITION: headline +55.9%. 10-Q Note 3's pro forma line puts Q2 2025 at $37.9M, not $35.049M, because Stereolabs closed Feb 4, 2026 - so like-for-like growth is +44.1%. Strip patent royalties from both sides and it is +39.3%. The Q3 guide midpoint of $56.0M is only +2.5% sequential and its $54.5M low end is BELOW the $54.626M just reported.
    - GROSS MARGIN, TESTED: we suspected the royalty did it and were mostly wrong. Holding royalties at Q1's $347,000 gives 47.4%, not 48.85% - so the royalty is ~146bp of the 595bp q/q gain. Product-only gross margin went 42.5% (Q1) to 47.0% (Q2) vs 45.2% a year ago: a real 450bp gain. The GAAP/non-GAAP gap is stock comp in COGS plus Stereolabs intangible amortisation.
    - BURN AND DILUTION: H1 operating cash flow -$20.039M vs -$6.188M a year earlier - burn TRIPLED while the adjusted EBITDA loss improved to $11.336M. With capex, H1 free cash flow was -$25.248M, 2.2x the adjusted EBITDA loss. $97.985M raised net on the ATM in H1. Shares outstanding 68,489,797 (Jun 30) to 72,112,333 (Jul 31) - 5.3% in 31 days.
    - BALANCE SHEET AND VALUATION: $262.5M cash and investments, ZERO debt, accumulated deficit $1.009B (a tax shield), book value $5.15/sh. At $43.40 on 72.11M shares, market cap $3.13B and EV ~$2.87B: 14.0x trailing revenue of $204.9M, 13.1x the annualised June run rate, 8.4x book. At the $61.25 target, EV is $4.15B = 20x sales.
    What to watch: UP: revenue +55.9% (a ~6% beat), gross margin 48.85% with product-only margin +450bp q/q, adjusted EBITDA loss cut to $4.453M, $262.5M cash and ZERO debt, a new cycle in Rev8. DOWN: 11 points of the growth rate is the Stereolabs deal and ~5 more a patent royalty; the Q3 guide midpoint is only +2.5% q/q with a low end BELOW Q2; H1 free cash flow -$25.2M; 5.3% of shares issued in one month.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    14 min
  • Revvity (RVTY) Q2 2026 Earnings: A 20-Cent Beat, 11 Cents A Tariff Refund
    Revvity, Inc. (RVTY) Q2 2026 — Q2 2026: revenue $729.7M, +1.3% y/y. GAAP EPS from continuing operations $0.48; adjusted $1.41 vs a $1.21 bar. But the release says $16M of tariff refunds sit inside that, about $0.11 of EPS. BMO Aug 4; the stock closed -3.32%.
    Revvity beat by 20 cents - $1.41 against $1.21 - and raised full-year guidance. Its own release says about $0.11 came from tariff refunds. Strip them and adjusted operating margin was FLAT. The stock closed down 3.32%.
    THE CALL: AVOID (2/5, THE BEAT IS REAL; ITS COMPOSITION IS THE PROBLEM) — base-case value ~$98.00 vs ~$114.66 today.
    KEY METRICS:
    - CALL: AVOID 2/5, fair value $98 vs the $114.66 close (-14.5%), 14.8% BELOW the $115 Street median. Base: trailing FCF $573M less the $16M tariff refund = $564M; 7%/4.5%/2.5% terminal at 8.25%. EV $13.07B (terminal 60.8%) less net debt over 111.6M shares = $97.57. Bull $132, bear $60.
    - THE PRINT: revenue $729.688M, +1.3% y/y; pro forma $711.109M, +4.5%, and 3% pro forma ORGANIC. GAAP EPS from continuing ops $0.48 vs $0.47; adjusted $1.41 vs $1.18 against a $1.21 bar. Adjusted operating income $211.0M, margin 28.9% vs 26.6%.
    - EPS BASIS, PROVEN NOT ASSUMED: 1.41 vs 1.21 is the ADJUSTED line, not GAAP's $0.48. FY2025 adjusted quarters 1.01+1.18+1.18+1.70 = $5.07 vs the $5.06 full-year adjusted EPS reported.
    - THE TARIFF REFUND: the release states adjusted operating income includes $16M of tariff refunds and adjusted EPS about $0.11. $16M on $729.7M is 219 basis points, against margin expansion of 230. Ex-refund the margin was 26.7% vs 26.6% - FLAT - and the beat shrinks to $0.09.
    - THE SHRINKING BASE: pro forma excludes China IDX, ~6% of FY2025 revenue, under a definitive agreement signed July 31, 2026 for up to $200M, closing by end-2027. Its revenue fell $39.7M to $18.6M (-53.2%) and operating income swung +$6.1M to -$4.4M.
    - SEGMENTS: Life Sciences $358.699M, -2.0%, pro forma ORGANIC -3%; adjusted operating income $111.534M, margin 31.1% vs 31.6%. Diagnostics $370.989M, pro forma +12%, organic +11%; adjusted operating income $112.866M, +26.2%, margin 30.4% vs 25.2%.
    - GUIDANCE WALK: Feb 2 initiated FY2026 adjusted EPS $5.35-5.45 (mid $5.40). May 5 rebased pro forma to $5.20-5.30. Aug 4 raised to $5.30-5.40 - a genuine LIKE-FOR-LIKE raise. But after $0.24 of beats the midpoint is $0.05 BELOW February, and H1 of $2.45 implies H2 of $2.90 vs ~$3.00 in May.
    - BALANCE SHEET: cash $1,022.9M; net debt $2,182.3M. Goodwill plus intangibles is 73% of assets, so TANGIBLE book is negative $14.36 a share. Q2 FCF $183.9M; H1 $299.0M, +28%. Intangible amortisation $84.9M a quarter is $0.76 of the $1.41.
    What to watch: UP: adjusted EPS $1.41 (+19.5%), adjusted operating margin 28.9% (+230bp), Diagnostics organic +11% with margin +520bp, a genuine like-for-like guidance raise to $5.30-5.40, H1 free cash flow +28%, $1.02B cash. DOWN: $0.11 of the $0.20 beat was tariff refunds, ex-refund margin FLAT, Life Sciences organic -3%, the FY midpoint is still below February's, the buyback has stopped.
    Also on YouTube: @ChargedAlpha
    DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.
    Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video
    Educational only. Not financial advice.
    14 min

About Charged Alpha Stock Encyclopedia

From the publisher's feed

⚡ Charged Alpha — The S&P 500 Stock Encyclopedia Data-driven deep dives into every stock in the S&P 500 after every earnings report. Each episode breaks down one company from open to close:…